for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shenzhen Salubris Pharmaceuticals Co Ltd

002294.SZ

Latest Trade

18.92CNY

Change

0.23(+1.23%)

Volume

1,340,454

Today's Range

18.69

 - 

18.98

52 Week Range

18.34

 - 

29.20

As of on the Shenzhen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
18.69
Open
18.69
Volume
1,340,454
3M AVG Volume
132.60
Today's High
18.98
Today's Low
18.69
52 Week High
29.20
52 Week Low
18.34
Shares Out (MIL)
1,046.02
Market Cap (MIL)
19,550.04
Forward P/E
16.17
Dividend (Yield %)
4.28

Latest Developments

More

Shenzhen Salubris Pharma's 9-Month Net Profit Down 37.7% Y/Y

Shenzhen Salubris Pharmaceuticals Plans To Buy Back Company Shares

Shenzhen Salubris Pharmaceuticals' H1 Net Profit Down 19.9% Y/Y

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shenzhen Salubris Pharmaceuticals Co Ltd

SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company provides two categories of products: pharmaceutical preparation and bulk drugs. The Company is also engaged in the research and development, production and sales of cardiovascular medical devices. The Company distributes its products within domestic market and to overseas markets.

Industry

Major Drugs

Contact Info

F37, Main Building,Chegong Temple

Lvgem NEO Square,No.6009 Shennan Boulvrd

Futian District

+86.755.83867888

http://www.salubris.cn/

Executive Leadership

Chenghai Ye

Chairman of the Board

Jun Liu

Finance Director

Kevin Sing Ye

General Manager, Director

Jie Yan

Deputy General Manager, Director

Ping Chen

Deputy General Manager

Key Stats

2.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

3.8K

2017

4.2K

2018

4.7K

2019(E)

4.8K
EPS (CNY)

2016

1.330

2017

1.390

2018

1.390

2019(E)

1.156
Price To Earnings (TTM)
19.07
Price To Sales (TTM)
4.18
Price To Book (MRQ)
2.99
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
5.55
LT Debt To Equity (MRQ)
3.42
Return on Investment (TTM)
14.76
Return on Equity (TTM)
12.94

Latest News

Latest News

BRIEF-Shenzhen Salubris Pharmaceuticals' Unit Plans To Invest In Mercator Medsystems Inc

* SAYS ITS UNIT PLANS TO INVEST $4.0 MILLION IN MERCATOR MEDSYSTEMS INC FOR 5.07 PERCENT STAKE Source text in Chinese: https://bit.ly/2FBt4H5 Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Shenzhen Salubris Pharmaceuticals holds 20 pct stake in electronic science and tech firm

* Says it holds 20 percent stake in a Sichuan-based electronic science and technology firm

BRIEF- Shenzhen Salubris Pharmaceuticals announces change in accounting policy

* Says it changes accounting policy based on accounting standards for business enterprises

BRIEF-Shenzhen Salubris Pharmaceuticals Says 2017 Net Profit Up 4.0 Percent Y/Y

* SAYS 2017 NET PROFIT UP 4.0 PERCENT Y/Y AT 1.45 BILLION YUAN ($231.03 million) Source text in Chinese: https://bit.ly/2Gsy7xH Further company coverage: ($1 = 6.2762 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Shenzhen Salubris Pharmaceuticals to invest 550 mln yuan in biotech unit

* SAYS IT PLANS TO INVEST 550 MILLION YUAN ($83.11 million) IN BIOTECH UNIT Source text in Chinese: http://bit.ly/2nqSdQS Further company coverage: ($1 = 6.6175 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Shenzhen Salubris Pharmaceuticals' net profits up in Q3, Jan-Sept

* Says Q3 net profit up 5.3 percent y/y at 363.6 million yuan ($54.78 million), 9-month net profit up 5.2 percent y/y at 1.1 billion yuan

BRIEF-Shenzhen Salubris Pharma's H1 net profit up 5.2 pct y/y

* Says H1 net profit up 5.2 percent y/y at 730.4 million yuan ($109.66 million)

BRIEF-Shenzhen Salubris Pharmaceuticals' controlling shareholder cuts stake in the company

* Says its controlling shareholder has cut 1.18 percent stake in the company on June 1, taking its holdings to 66.56 percent after transaction

BRIEF-Lock-up period for Salubris Pharmaceuticals' 556.4 mln shares to end

* Says lock-up period for 556.4 million shares to end, trading to start on May 26

BRIEF-Shenzhen Salubris Pharmaceuticals to pay FY 2016 annual div on May 12

* Says it will pay cash dividend of 7 yuan per 10 shares (before tax) to shareholders of record on May 11, for FY 2016

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up